This may explain the association between high levels of PD-1 expression on peripheral blood CD3+ T cells and CD8+ T cells and poor overall survival (OS) and progression-free survival (PFS) in patients with advanced-stage non-small cell lung cancer (NSCLC) treated with nivolumab (14). Here, CD8A is linked to non-small cell lung carcinoma.